ClinicalTrials.gg
RecruitingNCT07227402LITESPARK-033Updated Nov 12, 2026

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

A Phase 3 interventional study of Belzutifan and Zanzalintinib in Renal Cell Carcinoma, sponsored by Merck Sharp & Dohme LLC. Recruiting at 129 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Nov 12, 2026First site in Saudi ArabiaStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
904
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing zanzalintinib in Carcinoma, Renal Cell — 10 open to participants now, 12 under way, 4 of them phase 3. zanzalintinib · Carcinoma, Renal Cell.

Planned enrollment
3rd of 13
904 · median 140
Started
2025
with 2 others
Phase 3
4 of 13
3 open now
Primary completion
2032-02
later than 11 of 11 live
Registered
9th of 13
by date
Lead sponsor
3 of 13
Merck Sharp & Dohme LLC

Among the 13 studies testing zanzalintinib in Carcinoma, Renal Cell, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 9th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 13 studies testing zanzalintinib in Carcinoma, Renal Cell are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About zanzalintinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing zanzalintinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib.

The goal of this study is to learn if:

People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Carcinoma
  • Renal cell
  • Belzutifan
  • Zanzalintinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a confirmed diagnosis of unresectable, advanced renal cell cancer (RCC) with clear cell component (with or without sarcomatoid features) i.e., Stage IV renal cell cancer per American Joint Committee on Cancer (AJCC) (8th Edition)
  • Has per 1.1 (RECIST 1.1)
  • Has disease recurrence during adjuvant anti-programmed cell death 1/programmed cell death ligand 1 (/L1) therapy or recurrence ≤24 months following the last dose of anti-PD-1/L1 therapy
  • Has received no other prior systemic therapy for their RCC except for their adjuvant anti-PD-1/L1 therapy

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has cardiovascular disease within 12 months from first dose of study intervention, including Class III or IV congestive heart failure, unstable angina, new-onset angina, pulmonary embolism, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
  • Had deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
  • Has a ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
  • Has had major surgery within 8 weeks before randomization or has not adequately recovered from major surgery or has ongoing surgical complications
  • Has current pneumonitis/interstitial lung disease
  • Has symptomatic pleural effusion (for example cough, dyspnea, pleuritic chest pain), ascites, or pericardial fluid requiring drainage within 4 weeks prior to randomization
  • Has a gastrointestinal disorder including those associated with a high risk of perforation or fistula formation
  • Has a serious active nonhealing wound/ulcer/bone fracture
  • Has a requirement for hemodialysis or peritoneal dialysis
  • Has history of infection
  • Has or virus
  • Has pharmacologically uncompensated, symptomatic hypothyroidism
  • Received a live or within 30 days before the first dose of study intervention
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
904 participants (estimated)

Study arms

  • Experimental
    Belzutifan plus Zanzalintinib

    Participants will receive belzutifan orally once daily (QD) PLUS zanzalintinib orally QD until one of the reasons for discontinuation of study intervention are met.

    Drug: Belzutifan · Drug: Zanzalintinib

  • Active comparator
    Cabozantinib

    Participants will receive cabozantinib orally QD until one of the reasons for discontinuation of study intervention are met.

    Drug: Cabozantinib

Interventions

  • Administered orally QD

    Also known as: MK-6482, PT2977, WELIREG™

  • Administered orally QD

    Also known as: XL092

  • Administered orally QD

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD will be assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

    Time frame: Up to approximately 73 months

  2. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 73 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 73 months

  2. Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 73 months

  3. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.

    Time frame: Up to approximately 73 months

  4. Number of Participants Who Discontinue Study Treatment due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue the study treatment due to an AE will be reported.

    Time frame: Up to approximately 73 months

  5. Change From Baseline in European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) Global Health/Health-Related Quality of Life (HRQoL) Items 29 and 30 Combined Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent), then summed. Summed raw scores are standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome.

    Time frame: Up to approximately 25 months

  6. Change From Baseline in EORTC QLC-C30 Physical Functioning Items 1-5 Score

    The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome.

    Time frame: Up to approximately 25 months

  7. Change From Baseline in EORTC QLQ-C30 Role Functioning Items 6-7 Score

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Summed raw scores are standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better level of functioning.

    Time frame: Up to approximately 25 months

  8. Change From Baseline in Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score

    The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Responses are scored on a 5-point scale (0=Not at all to 4=Very much) and summed to generate an index symptom score. These scores can range from 0 to 36, with a higher score indicating more favorable kidney cancer symptom status.

    Time frame: Up to approximately 25 months

  9. Time From Baseline to First Deterioration in EORTC-QLC-C30 Global Health/HRQoL Score

    Time to True Deterioration (TTD) is defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in Items 29 and 30 scale scores. A longer TTD indicates a better outcome. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to approximately 25 months

  10. Time From Baseline to First Deterioration in EORTC-QLC-C30 Physical Functioning Score

    TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in physical functioning score (EORTC QLQ-C30 Items 1-5). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in physical functioning score will be presented. A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  11. Time From Baseline to First Deterioration in EORTC-QLC-C30 Role Functioning Score

    TTD is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in role functioning (EORTC QLQ-C30 Items 6 and 7) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10 point negative change (decrease) from baseline in role functioning score, will be presented. A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  12. Time From Baseline to First Deterioration in FKSI-DRS Score

    TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS Score. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

07

Study locations

129 of 129 sites recruiting
  • Alaska Oncology and Hematology ( Site 0133)
    Anchorage, Alaska 99508, United States
    Recruiting
    • Study Coordinator · Contact907-257-9851
  • Providence Medical Foundation ( Site 0141)
    Fullerton, California 92835, United States
    Recruiting
    • Study Coordinator · Contact714-446-5900
  • USC Norris Comprehensive Cancer Center ( Site 0126)
    Los Angeles, California 90033, United States
    Recruiting
    • Study Coordinator · Contact800-872-2273
  • Cedars-Sinai Medical Center ( Site 0112)
    Los Angeles, California 90048, United States
    Recruiting
    • Study Coordinator · Contact310-423-3227
  • New England Cancer Specialists ( Site 0132)
    Westbrook, Maine 04092, United States
    Recruiting
    • Study Coordinator · Contact207-303-3300
  • Greater Baltimore Medical Center ( Site 0145)
    Baltimore, Maryland 21204, United States
    Recruiting
    • Study Coordinator · Contact443-849-8136
  • Metro-Minnesota Community Clinical Oncology ( Site 0144)
    Saint Louis Park, Minnesota 55426, United States
    Recruiting
    • Study Coordinator · Contact952-993-1555
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131)
    Omaha, Nebraska 68130-2042, United States
    Recruiting
    • Study Coordinator · Contact402-691-6971
  • Carolina Oncology Specialists, PA ( Site 9002)
    Charlotte, North Carolina 28207, United States
    Recruiting
    • Study Coordinator · Contact704-342-1900
  • Thompson Cancer Survival Center ( Site 0125)
    Knoxville, Tennessee 37916, United States
    Recruiting
    • Study Coordinator · Contact865-331-1678
  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
    Nashville, Tennessee 37202, United States
    Recruiting
    • Study Coordinator · Contact615-312-3333
  • Hospital Aleman ( Site 0204)
    CABA, Buenos Aires C1118AAT, Argentina
    Recruiting
    • Study Coordinator · Contact+5448277000
  • Hospital Italiano de Buenos Aires. ( Site 0203)
    Caba, Buenos Aires C1199ABB, Argentina
    Recruiting
    • Study Coordinator · Contact+541149590200
  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205)
    Caba, Buenos Aires C1419AHN, Argentina
    Recruiting
    • Study Coordinator · Contact+541145740870
  • Instituto Alexander Fleming ( Site 0202)
    CABA, Buenos Aires C1426ANZ, Argentina
    Recruiting
    • Study Coordinator · Contact+541132218900
  • Hospital Universitario Austral ( Site 0212)
    Pilar, Buenos Aires B1629AHJ, Argentina
    Recruiting
    • Study Coordinator · Contact+542304387649
  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0208)
    Caba., Buenos Aires F.D. C1431FWO, Argentina
    Recruiting
    • Study Coordinator · Contact+541152990000
  • Sanatorio Parque ( Site 0201)
    Rosario, Santa Fe Province S2000DSV, Argentina
    Recruiting
    • Study Coordinator · Contact+5493416955611
  • Instituto de Oncología de Rosario ( Site 0209)
    Rosario, Santa Fe Province S2000KZE, Argentina
    Recruiting
    • Study Coordinator · Contact+5493414218909
  • Hospital Privado Universitario de Córdoba ( Site 0207)
    Córdoba, X5016KEH, Argentina
    Recruiting
    • Study Coordinator · Contact+543514688200
  • Macquarie University-MQ Health Clinical Trials Unit ( Site 2100)
    Sydney, New South Wales 2109, Australia
    Recruiting
    • Study Coordinator · Contact+61 2 9812 3526
  • Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0600)
    Linz, Upper Austria 4020, Austria
    Recruiting
    • Study Coordinator · Contact+43 732 7676 4641
  • Medizinische Universitat Wien ( Site 0601)
    Vienna, 1090, Austria
    Recruiting
    • Study Coordinator · Contact+43 1 40400 60430
  • Cliniques Universitaires Saint-Luc ( Site 0703)
    Brussels, Bruxelles-Capitale, Region de 1200, Belgium
    Recruiting
    • Study Coordinator · Contact+3227643546
  • Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 0701)
    Genk, Limburg 3600, Belgium
    Recruiting
    • Study Coordinator · Contact+32 89 80 40 40
  • UZ Gent ( Site 0702)
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
    • Study Coordinator · Contact+32 (0)9 332 62 18
  • UZ Leuven ( Site 0700)
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
    • Study Coordinator · Contact+32 (0)16 34 69 12
  • IPC - MT Instituto de Pesquisas Clínicas do Mato Grosso ( Site 0305)
    Cuiabá, Mato Grosso 78020-500, Brazil
    Recruiting
    • Study Coordinator · Contact+5565999470522
  • Liga Norte Riograndense Contra o Câncer ( Site 0307)
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Study Coordinator · Contact+558440095595
  • Hospital Moinhos de Vento ( Site 0309)
    Porto Alegre, Rio Grande do Sul 90560-032, Brazil
    Recruiting
    • Study Coordinator · Contact+5551980609999
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
    • Study Coordinator · Contact+551732015000
  • Hospital Alemao Oswaldo Cruz ( Site 0311)
    São Paulo, São Paulo 01327-001, Brazil
    Recruiting
    • Study Coordinator · Contact+551135490391
  • Oncocentro Valdivia ( Site 0408)
    Valdivia, Los Ríos Region 5112129, Chile
    Recruiting
    • Study Coordinator · Contact+56632632200
  • Fundacion Arturo Lopez Perez ( Site 0401)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56224457398
  • Centro de Investigacion Clinica UC CICUC ( Site 0402)
    Santiago, Region M. de Santiago 833000, Chile
    Recruiting
    • Study Coordinator · Contact56934331806
  • Klinički bolnički centar Sestre milosrdnice ( Site 0801)
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
    • Study Coordinator · Contact+38513787421
  • Klinički bolnički centar Zagreb ( Site 0800)
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
    • Study Coordinator · Contact+38512388575
  • Klinički Bolnički Centar Split ( Site 0802)
    Split, Split-Dalmatia County 21000, Croatia
    Recruiting
    • Study Coordinator · Contact+385915297299
  • Masarykuv onkologicky ustav ( Site 0903)
    Brno, Brno-mesto 656 53, Czechia
    Recruiting
    • Study Coordinator · Contact+420543136831
  • Fakultni nemocnice Ostrava ( Site 0904)
    Ostrava, Ostrava Mesto 708 52, Czechia
    Recruiting
    • Study Coordinator · Contact+420597374322
  • Nemocnice České Budějovice ( Site 0905)
    České Budějovice, 370 01, Czechia
    Recruiting
    • Study Coordinator · Contact+420387871111
  • Fakultni nemocnice Hradec Kralove ( Site 0902)
    Hradec Králové, 500 05, Czechia
    Recruiting
    • Study Coordinator · Contact+420 607 192 913
  • Fakultni nemocnice Olomouc ( Site 0901)
    Olomouc, 779 00, Czechia
    Recruiting
    • Study Coordinator · Contact+420588444295
  • Vseobecna fakultni nemocnice v Praze ( Site 0906)
    Prague, 128 08, Czechia
    Recruiting
    • Study Coordinator · Contact+420 224 966 405
  • Fakultni nemocnice v Motole ( Site 0900)
    Prague, 150 06, Czechia
    Recruiting
    • Study Coordinator · Contact+420224439427
  • Herlev Hospital ( Site 1002)
    Herlev, Capital Region 2730, Denmark
    Recruiting
    • Study Coordinator · Contact+45 38688798
  • Aarhus University Hospital Skejby ( Site 1001)
    Aarhus, Central Jutland 8200, Denmark
    Recruiting
    • Study Coordinator · Contact+45 91167192
  • Odense Universitetshospital ( Site 1000)
    Odense, Region Syddanmark 9000, Denmark
    Recruiting
    • Study Coordinator · Contact+45 65411516
  • CHU de Bordeaux Hop St ANDRE ( Site 1115)
    Bordeaux, Gironde 33075, France
    Recruiting
    • Study Coordinator · Contact+33556795679
  • Hôpital Foch ( Site 1118)
    Suresnes, Hauts-de-Seine 92150, France
    Recruiting
    • Study Coordinator · Contact+33146253671
  • Centre de Cancérologie du Grand Montpellier ( Site 1112)
    Montpellier, Herault 34070, France
    Recruiting
    • Study Coordinator · Contact+33467926155
  • CHU GRENOBLE ALPES ( Site 1101)
    La Tronche, Isere 38700, France
    Recruiting
    • Study Coordinator · Contact+33476765451
  • Centre d'Oncologie de Gentilly ( Site 1117)
    Nancy, Lorraine 54100, France
    Recruiting
    • Study Coordinator · Contact+33355685518
  • Centre Hospitalier Universitaire d'Angers-Urology ( Site 1104)
    Angers, Pays de la Loire Region 49933, France
    Recruiting
    • Study Coordinator · Contact+33665807200
  • Centre Hospitalier de la Cote Basque ( Site 1113)
    Bayonne, Pyrenees-Atlantiques 64109, France
    Recruiting
    • Study Coordinator · Contact+33559443535
  • centre hospitalier lyon sud ( Site 1102)
    Pierre-Bénite, Rhone 69310, France
    Recruiting
    • Study Coordinator · Contact+33472118088
  • CHU de Rouen ( Site 1108)
    Rouen, Seine-Maritime 76031, France
    Recruiting
    • Study Coordinator · Contact+33232881315
  • HENRI MONDOR HOSPITAL ( Site 1116)
    Créteil, Val-de-Marne 94010, France
    Recruiting
    • Study Coordinator · Contact+33145178243
  • CHD Vendee ( Site 1103)
    La Roche-sur-Yon, Vendee 85000, France
    Recruiting
    • Study Coordinator · Contact+33251446173
  • Klinikum Stuttgart - Katharinenhospital ( Site 1201)
    Stuttgart, Baden-Wurttemberg 70174, Germany
    Recruiting
    • Study Coordinator · Contact+49 7071 278 54564
  • UniversitaetsklInikum Tuebingen ( Site 1207)
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
    • Study Coordinator · Contact004970712987235
  • Universitätsmedizin Göttingen - Georg-August-Universität ( Site 1211)
    Göttingen, Lower Saxony 37075, Germany
    Recruiting
    • Study Coordinator · Contact+4955139 68145
  • Helios Kliniken Schwerin GmbH ( Site 1206)
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
    Recruiting
    • Study Coordinator · Contact+493855202120
  • Marienhospital Herne ( Site 1215)
    Herne, North Rhine-Westphalia 44625, Germany
    Recruiting
    • Study Coordinator · Contact+492323 4990
  • Universitaetsklinikum Muenster ( Site 1202)
    Münster, North Rhine-Westphalia 70174, Germany
    Recruiting
    • Study Coordinator · Contact+492518344658
  • Universitaetsklinikum Carl Gustav Carus Dresden ( Site 1213)
    Dresden, Saxony 01307, Germany
    Recruiting
    • Study Coordinator · Contact+493514584425
  • HELIOS Klinikum Erfurt ( Site 1208)
    Erfurt, Thuringia 99089, Germany
    Recruiting
    • Study Coordinator · Contact+493617810
  • Universitätsklinikum Jena ( Site 1204)
    Jena, Thuringia 07747, Germany
    Recruiting
    • Study Coordinator · Contact+4936419329901
  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1203)
    Berlin, 10117, Germany
    Recruiting
    • Study Coordinator · Contact+49 30 45050
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 1214)
    Hamburg, 20246, Germany
    Recruiting
    • Study Coordinator · Contact+4915222823094
  • Alexandra General Hospital of Athens ( Site 1300)
    Athens, Attica 115 28, Greece
    Recruiting
    • Study Coordinator · Contact+302132162543
  • Metropolitan Hospital ( Site 1302)
    Athens, Attica 185 47, Greece
    Recruiting
    • Study Coordinator · Contact+302104809667
  • University General Hospital ''Attikon'' - General Hospital of West Attica "H AGIA VARVARA" ( Site 1301)
    Chaïdári, Attica 124 62, Greece
    Recruiting
    • Study Coordinator · Contact+302105832549
  • Prince of Wales Hospital ( Site 2200)
    Hong Kong, Hong Kong
    Recruiting
    • Study Coordinator · Contact+85235051042
  • Queen Mary Hospital ( Site 2201)
    Hong Kong, Hong Kong
    Recruiting
    • Study Coordinator · Contact+85222554361
  • Cork University Hospital ( Site 1501)
    Cork, T12 YK23, Ireland
    Recruiting
    • Study Coordinator · Contact+353214234802
  • Tallaght University Hospital ( Site 1500)
    Dublin, D24 NR0A, Ireland
    Recruiting
    • Study Coordinator · Contact+35314144000
  • Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli ( Site 1609)
    Naples, Campania 80131, Italy
    Recruiting
    • Study Coordinator · Contact00390817472223
  • Istituto Nazionale Tumori Regina Elena ( Site 1611)
    Rome, Lazio 00144, Italy
    Recruiting
    • Study Coordinator · Contact+39 0652666919
  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1600)
    Milan, Milano 20133, Italy
    Recruiting
    • Study Coordinator · Contact00390223903028
  • Istituto Clinico Humanitas ( Site 1613)
    Rozzano, Milano 20089, Italy
    Recruiting
    • Study Coordinator · Contact00390282244061
  • Azienda Ospedaliera S. Luigi Gonzaga ( Site 1607)
    Orbassano, Piedmont 10043, Italy
    Recruiting
    • Study Coordinator · Contact00390119026534
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1601)
    Rome, Roma 00618, Italy
    Recruiting
    • Study Coordinator · Contact00390630155202
  • Azienda Ospedaliera Universitaria Careggi ( Site 1608)
    Florence, Tuscany 50134, Italy
    Recruiting
    • Study Coordinator · Contact+390557949648
  • Istituto Oncologico Veneto IRCCS ( Site 1612)
    Castelfranco Veneto, Veneto 31033, Italy
    Recruiting
    • Study Coordinator · Contact+39 0423.732336
  • Casa di Cura Dott. Pederzoli - UO Oncologia ( Site 1610)
    Peschiera del Garda, Veneto 37019, Italy
    Recruiting
    • Study Coordinator · Contact+390456444193
  • Azienda USL 8 di Arezzo ( Site 1605)
    Arezzo, 52100, Italy
    Recruiting
    • Study Coordinator · Contact+390575255446
  • A.O.U.C. Policlinico di Bari ( Site 1602)
    Bari, 70124, Italy
    Recruiting
    • Study Coordinator · Contact+390805592909
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1604)
    Bologna, 40138, Italy
    Recruiting
    • Study Coordinator · Contact+390512142575
  • Ospedale San Martino ( Site 1606)
    Genova, 16132, Italy
    Recruiting
    • Study Coordinator · Contact003901015553303
  • Azienda Ospedaliera Universitaria di Parma ( Site 1603)
    Parma, 43126, Italy
    Recruiting
    • Study Coordinator · Contact+39 0521702682
  • CIO - Centro de Inmuno-Oncología de Occidente ( Site 0503)
    Guadalajara, Jalisco 44630, Mexico
    Recruiting
    • Study Coordinator · Contact3331721132
  • I CAN ONCOLOGY CENTER S.A. DE C.V. ( Site 0507)
    Monterrey, Nuevo León 64710, Mexico
    Recruiting
    • Study Coordinator · Contact8125558165 Ext. 1005
  • Centro de Investigacion Clinica de Oaxaca ( Site 0502)
    Oaxaca City, Oaxaca 68020, Mexico
    Recruiting
    • Study Coordinator · Contact+529516035559
  • Higiea Oncologia ( Site 0504)
    Mexico City, 11810, Mexico
    Recruiting
    • Study Coordinator · Contact+525652731712
  • Clinica Integral Internacional de Oncología ( Site 0506)
    Puebla City, 72530, Mexico
    Recruiting
    • Study Coordinator · Contact+522229525806
  • AIDPORT Sp. z o.o. ( Site 1716)
    Skórzewo, Greater Poland Voivodeship 60-185, Poland
    Recruiting
    • Study Coordinator · Contact+48570783100
  • Zakład Diagnostyki Laboratoryjnej, Centrum Onkologii ( Site 1707)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
    Recruiting
    • Study Coordinator · Contact+48523743883
  • Pratia MCM Krakow ( Site 1713)
    Krakow, Lesser Poland Voivodeship 30-727, Poland
    Recruiting
    • Study Coordinator · Contact+48122958160
  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 1703)
    Krakow, Lesser Poland Voivodeship 31-826, Poland
    Recruiting
    • Study Coordinator · Contact+48126468251

Showing the first 100 of 129 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2032, 75 months after the start.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's planned 75 months is above that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2032 → Mar 2033, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 12, 2025
StartActual
Nov 26, 2025
Primary completionEst.
Feb 27, 2032
CompletionEst.
Mar 21, 2033was Feb 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Saudi Arabia
Show 2 added (1 United States, 1 Saudi Arabia)
  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000) · Nashville, United States
  • King Faisal Specialist Hospital and Research Center ( Site 2700) · Riyadh, Saudi Arabia
Nov 12, 2026
Study completion
Feb 27, 2032→Mar 21, 2033
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    2 sites added — first site in Saudi Arabia
    Show 2 added (1 United States, 1 Saudi Arabia)
    • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000) · Nashville, United States
    • King Faisal Specialist Hospital and Research Center ( Site 2700) · Riyadh, Saudi Arabia
    Study completion Feb 27, 2032→Mar 21, 2033
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07227402
Collaborators
Exelixis
Responsible party
Sponsor
First posted
Nov 12, 2025
Start date
Nov 26, 2025
Primary completion
Feb 27, 2032 (estimated)
Completion
Mar 21, 2033 (estimated)
Last update
Nov 12, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion